晚期早产期产前糖皮质激素治疗与双胎妊娠新生儿结局
该回顾性队列研究纳入2013年2月1日至2020年9月30日在中国一所大学附属医院分娩的1974例有晚期早产风险(34周0天至36周6天)的双胎妊娠孕妇。303例(15.3%)接受产前糖皮质激素治疗,1671例(84.7%)未接受。倾向评分重叠加权分析显示,治疗组与未治疗组新生儿主要复合呼吸系统并发症风险无显著差异(9.6% vs 2.5%;加权OR 1.27,95%CI 0.60-2.76)。亚组交互检验及敏感性分析均未显示显著差异。作者认为证据不足以表明双胎晚期早产期产前糖皮质激素治疗可降低新生儿疾病风险,可为临床实践提供参考。
要点
- 双胎妊娠晚期早产(34周0天至36周6天)产前糖皮质激素治疗组新生儿主要复合呼吸系统并发症发生率为9.6%(29/303),未治疗组为2.5%(41/1671)。
- 倾向评分重叠加权后,产前糖皮质激素治疗与新生儿主要结局风险无显著关联(加权OR 1.27,95%CI 0.60-2.76)。
- 按分娩孕周、分娩年份、绒毛膜性、至少1胎小于胎龄儿、双胎生长不一致及婴儿性别进行的亚组交互检验均无显著差异。
- 采用倾向评分匹配、不同给药至分娩间隔及将双胎婴儿作为个体分析的敏感性分析结果均无显著差异。
- 作者认为证据不足以表明双胎晚期早产期产前糖皮质激素治疗可降低新生儿疾病风险。
适用人群与场景
- 中国一所大学附属医院2013年2月1日至2020年9月30日分娩的双胎妊娠孕妇。
- 有晚期早产风险,即孕34周0天至36周6天。
研究设计与关键结果
- 研究类型:回顾性队列研究;样本量1974例双胎妊娠孕妇,其中303例(15.3%;平均[SD]母亲年龄30.8[4.2]岁)接受产前糖皮质激素治疗,1671例(84.7%;平均[SD]母亲年龄31.2[4.0]岁)未接受。
- 主要结局为新生儿复合呼吸系统疾病,定义为双胎中至少1名新生儿出现以下至少1项:呼吸窘迫综合征、机械通气、给予表面活性物质、因呼吸系统并发症转院或新生儿死亡。
- 倾向评分重叠加权分析显示,产前糖皮质激素治疗组与未治疗组新生儿主要结局风险无显著差异(29/303[9.6%] vs 41/1671[2.5%];加权OR 1.27,95%CI 0.60-2.76)。
- 按分娩孕周、分娩年份、绒毛膜性、至少1胎小于胎龄儿、双胎生长不一致及婴儿性别的亚组交互检验对新生儿主要结局均无显著差异;采用倾向评分匹配、不同给药至分娩间隔及将双胎婴儿作为个体分析的敏感性分析亦无显著差异。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为该队列研究证据不足以表明双胎妊娠晚期早产期产前糖皮质激素治疗可降低新生儿疾病风险,可为临床实践提供参考。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Antenatal corticosteroid treatment of individuals with singletons at risk for delivery during the late-preterm period has been academically recommended. However, the evidence on the use of antenatal corticosteroid treatment for twins at risk for delivery during the late-preterm period is still lacking.
OBJECTIVE: To evaluate whether antenatal corticosteroid treatment during the late-preterm period in twin pregnancies was associated with a lower risk of newborn morbidity.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study of twin pregnancies delivered from February 1, 2013, to September 30, 2020, in a university-affiliated hospital in China included 1974 individuals with twin pregnancies who were at risk for late preterm birth (34 weeks and 0 days to 36 weeks and 6 days of gestation). Data were analyzed from June 30 to July 13, 2023.
EXPOSURES: Antenatal corticosteroid treatment during the late-preterm period.
MAIN OUTCOMES AND MEASURES: The primary outcome measure was composite neonatal respiratory morbidity, defined as at least 1 of the following postnatal occurrences in at least 1 neonate of the twins: respiratory distress syndrome, mechanical ventilation, surfactant administration, transferred with respiratory complications, or neonatal death. Propensity score overlap weighting was used to analyze the association between antenatal corticosteroid treatment and the risk of neonatal outcomes.
RESULTS: The study population consisted of 1974 individuals with twin pregnancies, including 303 (15.3%; mean [SD] maternal age, 30.8 [4.2] years) who received antenatal corticosteroid treatment and 1671 (84.7%; mean [SD] maternal age, 31.2 [4.0] years) who did not receive antenatal corticosteroid treatment. The propensity score overlap weighting showed no significant differences between the antenatal corticosteroid treatment group and the no-antenatal corticosteroid treatment group in the risk of neonatal primary outcome (29 of 303 [9.6%] vs 41 of 1671 [2.5%]; weighted odds ratio, 1.27 [95% CI, 0.60-2.76]). None of the subgroup interaction tests were significant for the neonatal primary outcome in terms of gestational age at delivery, year of delivery, chorionicity, at least 1 infant small for gestational age, intertwin growth discordance, and infant sex, and neither was the sensitivity analysis of using propensity score matching and a different administration-to-birth interval and treating twin infants as individuals.
CONCLUSIONS AND RELEVANCE: This cohort study found insufficient evidence that antenatal corticosteroid treatment during the late-preterm period in twin pregnancies could be associated with a lower risk of newborn morbidity. This new finding can provide a reference for clinical practice.
参考来源
- Zhu J, Zhao Y, An P, et al. Antenatal Corticosteroid Treatment During the Late-Preterm Period and Neonatal Outcomes for Twin Pregnancies. JAMA Netw Open. 2023. PMID: 37976061. doi:10.1001/jamanetworkopen.2023.43781
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。